TITAN PHARMACEUTICALS INC (TTNP) - Dilution Analysis

POS AM filing: Registration Statement on Form S-3 registering the issuance from time to time of up to $50,000,000 of any combination of the Company's common stock, preferred stock, debt securities, and/or warrants.

POS AM filing: Registration Statement on Form S-3, File No. 333-230742, originally filed with the SEC on April 5, 2019 and declared effective on April 24, 2019, registering the issuance from time to time of up to $50,000,000 of any combination of the Company's common stock, preferred stock, debt securities, and/or warrants

8-K filing: Titan Pharmaceuticals, Inc. entered into a Securities Purchase Agreement with Blue Harbour Asset Management L.L.C-FZ, issuing 60,000 shares of Series C Convertible Preferred Stock at $10.00 per share for $600,000 in a private placement that was completed on June 27, 2025. ($0.6M proceeds)

10-Q filing | 0.9M shares outstanding

8-K filing: Titan Pharmaceuticals, Inc. completed a private placement with Blue Harbour Asset Management L.L.C-FZ on April 11, 2025, issuing 100,000 shares of Series B Convertible Preferred Stock at $10.00 per share for $1,000,000. ($1.0M proceeds)

8-K filing: Titan Pharmaceuticals, Inc. entered into a Securities Purchase Agreement with Blue Harbour Asset Management L.L.C-FZ to issue 100,000 shares of Series B Convertible Preferred Stock at $10.00 per share for an aggregate purchase price of $1,000,000 in a private placement. ($1.0M proceeds)

10-K filing | 0.9M shares outstanding

10-Q filing | 0.9M shares outstanding

10-Q filing | 0.9M shares outstanding

10-Q filing | 0.9M shares outstanding

RW filing: The company decided not to pursue the offering due to market conditions and no longer wishes to conduct a public offering of securities at this time and requests withdrawal of the registration statement.

10-K filing | 0.9M shares outstanding

8-K filing: Titan Pharmaceuticals, Inc. issued 54,132 shares of common stock to Choong Choon Hau in connection with the conversion of a $500,000 convertible promissory note at a conversion price of $9.32 per share.

8-K filing: Stock split 1-for-20 | Outstanding: 15,016,000 → 750,800

10-Q filing | 15.0M shares outstanding

8-K filing: Titan Pharmaceuticals, Inc. entered into a Securities Purchase Agreement with The Sire Group Ltd. to issue 950,000 shares of Series AA Convertible Preferred Stock at $10.00 per share for an aggregate purchase price of $9,500,000 in a private placement. ($9.5M proceeds)

10-Q filing | 15.0M shares outstanding

8-K filing: Titan Pharmaceuticals granted an aggregate of 450,000 shares of unrestricted common stock to six members of the Board of Directors and one member of the management team on July 26, 2023, which vested immediately.

S-1 filing: Titan Pharmaceuticals, Inc. is offering shares of its common stock at an assumed public offering price. The last reported sale price of the common stock on June 22, 2023, was $0.73 per share.

10-Q filing | 15.0M shares outstanding

10-K filing | 15.0M shares outstanding

10-Q filing | 14.6M shares outstanding

10-Q filing | 13.7M shares outstanding

10-Q filing | 12.0M shares outstanding

S-1/A filing: This filing describes multiple offerings of warrants and common stock.

10-K filing | 9.7M shares outstanding

8-K filing: Titan Pharmaceuticals, Inc. executed a registered direct offering of 1,100,000 shares of common stock and 2,274,242 pre-funded warrants, along with a concurrent private placement of pre-funded warrants for 1,289,796 shares and warrants for 4,664,038 shares.

10-Q filing | 9.9M shares outstanding

10-Q filing | 9.9M shares outstanding

10-Q filing | 9.9M shares outstanding

10-K filing | 9.9M shares outstanding

S-1 filing: The filing discusses the possibility of future offerings of common stock or securities convertible into common stock to raise additional capital, and the potential risks associated with such offerings, including dilution and market volatility.

8-K filing: Titan Pharmaceuticals, Inc. entered into a Securities Purchase Agreement to issue 2,725,000 shares of common stock at $3.55 per share for gross proceeds of $9.7 million and is also selling warrants to purchase an aggregate of 2,725,000 shares of common stock at an exercise price of $3.55 in a concurrent private placement. ($9.7M proceeds)

S-1 filing: S-1 filing describing warrant issuances in connection with registered direct offerings in August 2019 and January 2020.

8-K filing: Stock split 1-for-30 | Outstanding: 196,763,180 → 6,650,000

10-Q filing | 196.8M shares outstanding

8-K filing: Titan Pharmaceuticals, Inc. completed a public offering of 80,000,000 units at $0.10 per unit, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock; the company is also seeking stockholder approval for a reverse stock split. ($8.0M proceeds)

S-1/A filing: The company is offering units, each consisting of one share of common stock and a warrant to purchase one share of common stock, underwritten by Maxim Group LLC.

S-1/A filing: The filing is an S-1/A amendment related to an offering of units, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock.

8-K filing: Titan Pharmaceuticals, Inc. entered into a Share Purchase Agreement with accredited institutional investors for a registered direct offering of 19,440,000 shares of common stock at $0.14 per share, expecting gross proceeds of approximately $2.7 million. ($2.7M proceeds)

10-Q filing | 97.2M shares outstanding

10-Q filing | 95.7M shares outstanding

10-K filing | 93.5M shares outstanding

8-K filing: Titan Pharmaceuticals, Inc. reports an increase in shares outstanding of common stock from 57,378,794 on December 31, 2019 to 93,467,258 on March 16, 2020 due to the sale of equity securities and exercise of outstanding warrants.

8-K filing: Titan Pharmaceuticals, Inc. entered into a Securities Purchase Agreement to issue 8,700,000 shares of common stock and warrants to purchase 8,700,000 shares of common stock, and may undergo a reverse stock split pending stockholder approval to allow warrant exercise. ($2.2M proceeds)